Evaluating neurobehavioral functions in newly diagnosed primary CNS lymphoma patients receiving advanced radiation therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients newly diagnosed with primary central nervous system lymphoma (PCNSL) who will receive hyperfractionated conformal whole-brain radiation therapy combined with a simultaneous integrated boost. The aim is to achieve effective tumor control while minimizing neurocognitive decline, a common side effect of traditional treatments. Patients will undergo a thorough neurobehavioral and neurocognitive assessment to evaluate the impact of this treatment approach. The study seeks to provide insights into the balance between effective cancer treatment and the preservation of cognitive functions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients must have a histopathologic diagnosis of non-Hodgkin's lymphoma (NHL) by brain biopsy
* A typical MRI/CT scan for primary CNS lymphoma is defined as the presence of hypo, iso, or hyperintense parenchymal contrast-enhancing (usually homogeneously) mass lesion(s)
* Patients must have a normal or negative pre-treatment systemic evaluation including: i. A bone marrow aspirate and biopsy ii. CT scans of the chest, abdomen and pelvis iii. Patients must have adequate bone marrow reserve
* Patients must be HIV-1 negative
* Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatment

Exclusion Criteria:

* A past history of major psychiatric disease
* Prior cranial irradiation for any reasons
* Other active primary cancer with the exception of basal cell carcinoma of skin and cervical carcinoma in situ
* Pre-existing immunodeficiency such as renal transplant recipient

Where it's running

• Chang Gung Memorial Hospital
  Taoyuan, Taiwan Recruiting

Study contacts

• Study coordinator: Chi-Cheng Chuang, M.D.
• Email: ccc2915@cgmh.org.tw
• Phone: +886-33281200

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treatment protocol for B-cell mature non-Hodgkin's lymphoma in children and adolescents

  This study is testing different treatment plans for children and teenagers with B-cell non-Hodgkin's lymphoma to see who needs stronger therapy and who can safely have gentler options.

  Recruiting Phase 4 Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Moscow, RF · NCT05518383

• CSF DNA testing to improve diagnosis and monitoring in primary CNS lymphoma

  This project will test whether sequencing DNA from spinal fluid can help diagnose and monitor people with suspected or confirmed primary CNS lymphoma.

  Recruiting IRCCS San Raffaele · Milan, Italy/Lombardy · NCT05036564

• Using advanced MRI to detect primary CNS lymphoma

  This study is testing a new type of MRI to see if it can help doctors better detect and monitor primary central nervous system lymphoma in patients.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT04656431

• Lenalidomide and Rituximab for Patients with Primary CNS Lymphoma Who Can't Have Transplants

  This study is testing if a combination of two medications, lenalidomide and rituximab, can help older patients or those in poor health with primary CNS lymphoma who can't have a stem cell transplant stay healthy longer after their initial treatment.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT04627753

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.